This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Antrin

AbbVie Inc.

Drug Names(s): motexafin lutetium

Description: Antrin is taken up into atherosclerotic plaques, specifically into macrophages, which are thought to be involved in inflammation and destabilization of the plaques. When Antrin is activated by phototherapy, it induces apoptosis in the macrophages.

Deal Structure: Pharmacyclics and AbbVie
In March 2015, AbbVie announced a definitive agreement under which AbbVie will acquire Pharmacyclics. Under the terms of the transaction, AbbVie will pay $261.25 per share comprised of a mix of cash and AbbVie equity.

In May 2015, AbbVie announced that it has completed the acquisition of Pharmacyclics.


Antrin News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug